{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
<< Return to MedStarHealth.org
MedStar Health
  • Sign In
  • Conferences
  • RSS
  • Online Courses
  • Learning from Teaching
  • Podcasts
  • Contact Us
Close Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##
MedStar associates, you will log in to CloudCME with your SiTEL Learning Management System (SITELMS) account on the next screen.

If you are not a MedStar associate, you can log in or create an account on the next screen.

For login assistance, contact the SiTEL Help Center at 1-855-745-1861 (Mon-Fri 8 AM to 5 PM) or at [email protected]
I am a MedStar Associate (login via SiTEL)
I am Not a MedStar Associate
Enter your email and password to login:



Login

New to CloudCME? Create an Account:

Create New Account
Back to Login Provider Forgot Your Password?

Forgot Your Password?







Back to Login
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##






Password Requirements

  • Must be between 8 and 16 characters in length
  • Must Contain at least 1 upper case character
  • Must Contain at least 1 lower case character
  • Must contain at least 1 numeric character
  • Must contain at least 1 of the following ! * @ # $ % ^ & + =


  • -- Select Degree --
  • AAS
  • BSN
  • BSND
  • BSRT
  • CCT
  • CNM
  • CRNP
  • CRNP, RN
  • CVT
  • DNP
  • DO
  • DPM
  • DPM, MS
  • DPM. MPH
  • DPT
  • JD
  • LCSW-C
  • LMSW
  • LPN
  • MA
  • MBBS, DTMH
  • MD
  • MD, FACC
  • MD, FACS
  • MD, JD
  • MD, MBA
  • MD, MPH
  • MD, MSc, MBA
  • MD, PhD
  • MD, PhD, MS
  • MGC, CGC
  • MPH
  • MS
  • MS, MPH, CGC
  • MSN
  • MSOTR/L, CLT
  • MSPH
  • MSW
  • None
  • NP
  • Other
  • OTR
  • PA
  • PharmD
  • PhD
  • PT
  • PT, DPT
  • RCES
  • RCIS
  • RD
  • RDN
  • RN
  • RN, BSN
  • RN, BSN, CCRN, CWON
  • RT

Please enter your degree:





Back to Login
Close Search Site Search: Enter your search terms in the field below to view results.
Close Specialties
{1}
##LOC[OK]##
{1}
##LOC[OK]## ##LOC[Cancel]##
{1}
##LOC[OK]## ##LOC[Cancel]##

Advances in the Management of Prostate, Kidney, and Bladder Cancers 2023


Advances in the Management of Prostate, Kidney, and Bladder Cancers 2023 Banner

  • Overview
  • Register
  • Faculty
  • Schedule
  • Venue
  • Exhibitors
Add to Calendar Advances in the Management of Prostate, Kidney, and Bladder Cancers 2023 9/29/2023 12:00:00 PM 9/30/2023 4:50:00 PM America/New_York For More Details: https://medstar.cloud-cme.com/course/courseoverview?P=0&EID=26711 Marriott Georgetown false MM/DD/YYYY


Date & Location
Friday, September 29, 2023, 12:00 PM - Saturday, September 30, 2023, 4:50 PM, Marriott Georgetown, Washington, DC

Target Audience
Specialties - Medical Oncology, Oncology, Pathology, Radiation Oncology, Radiology, Surgery, Urology
Professions - Non-Physician, Nurse, Physician, Student

Overview
MedStar Health is proud to present this blended conference to bring you the most up-to-date comprehensive care and education for the kidney, bladder, and prostate. During this meeting, you can attend high-caliber lectures with questions and discussion time focusing on these three cancer areas. Expert faculty will deliver state-of-the-art lectures that will include treatment approaches, clinical trials, biologic and genomic factors, and future directions. Presentations will also discuss emerging controversies and ongoing research aimed at addressing them. Advances in Prostate Cancer reviews recent advances in the diagnosis and treatment of patients with localized and advanced prostate cancer. Key clinical topics will include the use of biomarkers and modern imaging technologies in the management of early-stage prostate cancer as well as advances in the multidisciplinary approach to patients with high-risk, locally advanced, relapsed non-metastatic, and metastatic prostate cancer. Applications of new therapeutic agents, cutting-edge radiation technology, combined modality strategies, and evolving minimally invasive urologic surgical approaches will also be discussed. Advances in Kidney Cancer will review the approaches to the treatment of patients with small renal masses and the role of cytoreductive nephrectomy and an update on adjuvant therapy. Expert speakers will also present the latest front line and subsequent systemic therapy approaches as well as the treatment of patients with non-clear cell RCC. Advances in Bladder Cancer is a comprehensive session that explores the latest advances in bladder cancer diagnosis, management, and treatment. With a focus on innovative approaches and emerging therapies, participants will gain valuable insights into various aspects of bladder cancer care. During the lectures, it will covers a range of topics, including BCG unresponsive non-muscle invasive bladder cancer, management strategies for muscle invasive bladder cancer, and cutting-edge developments in bladder cancer surgery. Additionally, the talks delves into clinical trials, upper tract urothelial carcinoma, and advances in systemic therapy for metastatic urothelial carcinoma, ensuring a well-rounded understanding of the current bladder cancer landscape. These talks were designed for healthcare professionals, researchers, and students who are looking to enhance their knowledge and stay up-to-date with the latest developments in the field of bladder cancer care.


Objectives
After completing this activity, the participant will be able to:

  1. Identify the roles and responsibilities of members of the healthcare team involved in the collaborative care of patients with prostate, kidney, and bladder cancers.
  2. Describe emerging treatments, endpoints, and predictive biomarkers for RCC management.
  3. Describe the role of immunotherapy and novel targeted therapies for upper tract and chemotherapy-refractory carcinoma.
  4. Describe symptom management, supportive care, procedural, and pharmacological basis of treating prostate and bladder cancers.
  5. Integrate a team-based approach in the care of patients with prostate, kidney, and bladder cancers.
  6. Discuss the current treatment algorithm for patients with metastatic clear cell and non-clear cell RCC.
  7. Describe the evolving role of surgery in the management of patients with all stages of kidney cancer.
  8. Discuss the evolving roles of urology and medical oncology in the management of localized bladder cancer.
  9. Discuss the recent advances in multi-modality evaluation and management of early stage of prostate cancer.
  10. Discuss the biology and evolving therapeutics for advanced prostate cancer.

Registration

Physician: $150  
Resident and Fellow: $50  
Physician Assistant: $50  
Nurse Practitioner: $50  
Nurse: $50  
Allied Health Professional: $50
Medical Student: $50
Industry Professional: $200


Accreditation

In support of improving patient care, MedStar Health is jointly accredited by the Accreditation Council for Continuing Medical Education(ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC) to provide continuing education for the healthcare team.



Credit Designation Statement:

  

This activity was planned by and for the healthcare team and learners will receive 10.50 Interprofessional Continuing Education (IPCE) credits for learning and change.

 

Physicians: MedStar Health designates this live activity for a maximum of 10.50 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. 

American Board of Internal Medicine MOC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 10.50 MOC points in the American Board of Internal Medicine’s (ABIM) Maintenance of Certification (MOC) program. It is the CME activity provider’s responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.

American Board of Surgery CC Credit

Successful completion of this CME activity, which includes participation in the evaluation component, enables the learner to earn credit toward the CME and Self-Assessment requirements of the American Board of Surgery’s Continuous Certification program. It is the CME activity provider's responsibility to submit learner completion information to ACCME for the purpose of granting ABS credit.

MOC Participation Threshold
Learner participates by writing a reflective statement and makes a commitment to change or maintain an element of practice.

Nurses: This activity is approved for 10.50 ANCC contact hours. Nurses should claim only the credit commensurate with the extent of their participation in the activity.


Credits
AMA PRA Category 1 Creditsâ„¢ Physician (10.50 hours), Nurse - ANCC (10.50 hours), Non-Physician Member of the Healthcare Team (10.50 hours), IPCE (10.50 hours), ABIM MOC Part 2 (10.50 hours), ABS CC (10.50 hours)

Washington Marriott Georgetown 
1221 22nd St NW
Washington, DC 20037
(202) 872-1500
Hotel Website



Mitigation of Relevant Financial Relationships


MedStar Health adheres to the ACCME’s Standards for Integrity and Independence in Accredited Continuing Education.

Individuals in a position to control the content of this CE activity, including faculty, planners, reviewers, or others are required to disclose all relevant financial relationships with ineligible companies. An ineligible company is any entity whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients. All of the relevant financial relationships listed below have been mitigated prior to the commencement of the activity.



Faculty Member Information
Role in activity
Name of Ineligible Company(s) / Nature of Relationship(s)
Faculty Photos
Michael B. Atkins, MD
Deputy Director, Georgetown Lombardi Comprehensive Cancer Center, William M. Scholl, Staff Physician, Division of Hematology/Oncology, Professor and Vice-Chair Department of Oncology
MedStar Georgetown University Hospital, Georgetown University School of Medicine
Washington, DC
Activity Co-Director
Advisor-Aveo Pharmaceuticals|Advisor-BMS|Advisor-Eisai|Consulting Fee-Exelixis|Advisor-Genentech, Inc.|Advisor-GlaxoSmithKline|Advisor-Merck (Merck Sharp & Donhme a subsidiary of Merck & Co, Inc.)|Advisor-Novartis Pharmaceuticals (Relationship has ended)|Advisor-Pfizer, Inc.|Advisor-Roche|Consulting Fee-Sanofi|Advisor-Takeda|Advisor-Wolters Kluwer
Faculty Photos
Mohit Gupta, MD
Urologic Oncologist, Director, Clinical Research for the Department of Urology
Medstar Georgetown University Hospital
Washington, DC
Activity Co-Director
Nothing to disclose
Faculty Photos
Keith J. Kowalczyk, MD
Co-Director, Urologic Oncology; Associate Professor, Urology
MedStar Georgetown University Hospital, MedStar Washington Hospital Center, Georgetown University School of Medicine
Washington, DC
Activity Co-Director
Nothing to disclose
Faculty Photos
Ross E. Krasnow, MD
Staff Physician, Urologic Oncology
MedStar Washington Hospital Center
Washington, DC
Activity Co-Director
Nothing to disclose
Faculty Photos
Young Kwok, MD
Professor, Radiation Oncology
Maryland Proton Treatment Center, University of Maryland Medical Center, University of Maryland School of Medicine
Baltmore , MD
Activity Co-Director
Nothing to disclose
Faculty Photos
Paul Leger, MD, MPH
MedStar Georgetown University Hospital
Washington, DC
Activity Co-Director
Nothing to disclose
Faculty Photos
Suthee Rapisuwon, MD
Attending Physician, Hematology-Oncology, Assistant Professor, Oncology
MedStar Georgetown University Hospital, Georgetown University School of Medicine
Washington, DC
Activity Co-Director
Advisor-Castle Biosciences|Consulting Fee-Replimmune|Grant or research support-Bristol-Myers Squib Aventis
Faculty Photos
George K. Philips, MD
Vice Chair, Department of Medicine, Staff Physician, Hematology/Oncology
MedStar Georgetown University Hospital, Georgetown Lombardi Comprehensive Cancer Center
Washington, DC
Activity Co-Director Content Reviewer
Nothing to disclose
Faculty Photos
Kellie Gardner, NP
Nurse Practitioner
MedStar Georgetown University Hospital
Washington, DC
Planning Committee Member
Nothing to disclose

Friday, September 29, 2023
Registration Open
12:00PM - 12:45PM
Session I: Prostate Cancer
12:45PM - 4:45PM
Welcome Remarks and Introduction
12:46PM - 12:50PM
Updates in Prostate Cancer Screening
12:50PM - 1:10PM
Optimizing Prostate Biopsy/MRI vs High-Frequency Ultrasound in the Detection of Prostate Cancer
1:10PM - 1:30PM
Active Surveillance High Genetic Risk Patients
1:30PM - 1:50PM
Prostate Cancer Panel Discussion I
1:50PM - 2:05PM
Afternoon Break and Visit Exhibits
2:05PM - 2:20PM
Fascia-Sparing Robot-Assisted Radical Prostatectomy
2:20PM - 2:40PM
Management of Post-Prostatectomy Stress Urinary Incontinence Complications
2:40PM - 3:00PM
Radiation Therapy
3:00PM - 3:20PM
Topic: TBD
3:20PM - 3:40PM
PSMA/Theranostics
3:40PM - 4:00PM
Keynote: Medical Oncology: Castrate Resistant Prostate Cancer – Ordering of Treatment
4:00PM - 4:30PM
Prostate Cancer Panel Discussion II
4:30PM - 4:45PM
Networking Reception with Exhibitors
4:45PM - 5:45PM
Saturday, September 30, 2023
Breakfast, Registration, and Visit the Exhibits
7:30AM - 8:30AM
Session II: Kidney Cancer
8:30AM - 1:30PM
To Treat or Not to Treat: The Adjuvant Therapy Morass
8:31AM - 8:50AM
Surgical Management in Metastatic RCC
8:50AM - 9:10AM
First Line Therapy-IO/IO vs IO/TKI – Debate
9:10AM - 9:40AM
The Treatment Choice Dilemma in Favorable Risk RCC
9:40AM - 10:00AM
Subsequent Therapy Options and Sequencing
10:00AM - 10:20AM
Kidney Cancer Panel Discussion I
10:20AM - 10:35AM
Morning Break and Visit the Exhibits
10:35AM - 10:45AM
Update on Minimally-Invasive Surgical Management of RCC
10:45AM - 11:05AM
Focal Therapy Update
11:05AM - 11:25AM
Non-Clear Cell RCC
11:25AM - 11:45AM
Biomarkers and Alternative Endpoints
11:45AM - 12:15PM
Kidney Cancer Panel Discussion II
12:15PM - 12:30PM
Lunch and Visit the Exhibits
12:30PM - 1:30PM
Session III: Bladder Cancer
1:30PM - 4:50PM
BCG Unresponsive NMIBC
1:31PM - 1:50PM
TMT and Bladder Preservation for Patients with MIBC
1:50PM - 2:10PM
Surgical Management of Bladder Cancer
2:10PM - 2:30PM
Bladder Cancer Panel Discussion I
2:30PM - 2:45PM
Afternoon Break and Visit the Exhibits
2:45PM - 3:00PM
Keynote: Updates in NMIBC Trials
3:00PM - 3:20PM
Perioperative Systemic Therapy in UTUC
3:20PM - 3:50PM
Advances in Systemic Therapy for Advanced Urothelial Carcinoma
3:50PM - 4:10PM
Implementing Smoking Cessation for Bladder Cancer Patients
4:10PM - 4:30PM
Bladder Cancer Panel Discussion II
4:30PM - 4:45PM
Closing Remarks and Conference Adjourn
4:45PM - 4:50PM

If you are interested in supporting the program, please contact Elizabeth Romano at [email protected]

Contact Us

MedStar Health, Department of Continuing Professional Education
[email protected]
CE.MedStarHealth.org